Noveome Biotherapeutics, Inc., a Pittsburgh, PA-based clinical-stage biopharmaceutical company focused on developing next-generation biologics for the promotion and restoration of cellular integrity of inflamed or damaged tissues, closed a $15m Series D financing.
The round was led by a new institutional investor in addition to existing investors. Prior to this financing, Noveome has raised a total of $144m in capital from both private equity investors and non-dilutive capital from the U.S. Department of Defense and the Commonwealth of Pennsylvania and Allegheny County.
The company intends to use the funds for the advancement of its clinical stage programs investigating its proprietary, cell-free platform biologic, ST266, for the treatment of both ophthalmological and central nervous system (CNS) disorders.
Led by William J. Golden, Founder, Chairman and Chief Executive Officer, Noveome Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing next-generation biologics for the promotion and restoration of cellular integrity of inflamed or damaged tissues. Its multi-target platform biologic and lead product, ST266, is a complex, non-cellular product containing hundreds of biologically active proteins and other biologic factors.
ST266 is currently being evaluated in multiple indications across CNS, ophthalmic, pulmonary and gastrointestinal therapeutic areas.
FinSMEs
09/04/2019